Reasearch Awards nomination

Email updates

Keep up to date with the latest news and content from Lipids in Health and Disease and BioMed Central.

Open Access Research

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects

Jeffrey B Rosen1*, Jose G Jimenez2, Valdis Pirags3, Hella Vides4, Rachid Massaad5, Mary E Hanson6, Philippe Brudi6 and Joseph Triscari6

Author Affiliations

1 Clinical Research of South Florida, Coral Gables, FL, USA

2 Hospital CIMA San Jose, Escazu, San Jose, Costa Rica

3 University of Latvia, Riga, Latvia

4 Viljandi Hospital, Vildjandimaa, Estonia

5 MSD Belgium, Brussels, Belgium

6 Merck & Co, Inc., Whitehouse Station, NJ, USA

For all author emails, please log on.

Lipids in Health and Disease 2013, 12:103  doi:10.1186/1476-511X-12-103

Published: 16 July 2013

Abstract

Purpose

This post hoc analysis assessed switching to ezetimibe/simvastatin 10/20 mg vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg in subgroups of obese (BMI ≥30 kg/m2) and non-obese (BMI <30 kg/m2) diabetic subjects.

Methods

This was a randomized, double-blind, 12-week study of adults 18–79 years with cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. Percent change in LDL-C and other lipids was estimated.

Results

In obese subjects (n = 466), percent changes in LDL-C and most other lipids were greater with ezetimibe/simvastatin vs doubling the baseline statin dose or switching to rosuvastatin. In non-obese subjects (n = 342), percent changes in LDL-C, total cholesterol, non-HDL-C, Apo B and Apo A-I were greater with ezetimibe/simvastatin vs doubling the baseline statin dose or switching to rosuvastatin; and treatment with ezetimibe/simvastatin resulted in greater changes in triglycerides vs rosuvastatin and HDL-C vs doubling the baseline statin dose. The safety profiles were generally similar.

Conclusions

Regardless of baseline obesity status, switching to ezetimibe/simvastatin was more effective at reducing LDL-C, total cholesterol, non-HDL-C, and Apo B vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg.

Keywords:
Atorvastatin; Ezetimibe; Diabetes; Obesity; Rosuvastatin; Statin